SR Pharma plc Announces Encouraging Results for Atu027 RNAi Showing Therapeutic Efficacy in Mouse Models of Pancreatic Cancer
SR Pharma plc and its operating subsidiary Atugen AG announce that studies at the Charité Hospital, Berlin have demonstrated the therapeutic efficacy of Atu027 RNAi in animal models of pancreatic cancer. The data showed both inhibition of cancer growth and prevention of metastatic spread, demonstrating potent efficacy and effective delivery, with no adverse events. These promising data support the clinical development program for Atu027 RNAi for pancreatic cancer which is scheduled to enter human clinical trials in 2007. Atu027 RNAi is an novel therapeutic drug being developed based on small interfering RNA.
Atugen has concentrated its efforts to meet this medical need by developing Atu027 RNAi. In these studies, mice with human pancreatic cancer were injected with Atu027 RNAi, a modified and stabilized small interfering RNA drug, formulated in a proprietary liposomal based delivery system (AtuPLEX). Atu027 RNAi works by specifically targeting PKN3, a proprietary protein kinase target.
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.